A valine-alanine linker is widely used in bioconjugation, particularly in the development of antibody-drug conjugates (ADCs). These linkers are designed to connect a drug payload to an antibody, allowing for targeted delivery and release of the drug to specific cancer cells.
Advantages:
- Valine-alanine linkers are stable in the bloodstream, which reduces the risk of premature drug release and minimizes the off-target effects.
- Valine-alanine linkers are cleaved by specific enzymes that are often overexpressed in target cells, such as cancer cells. This ensures that the drug is released precisely where it is needed.
- Valine-alanine linkers help reduce systemic toxicity and improve the therapeutic index of the drug by target specific delivery and release of the drug in the target cancer cells.
- Val-Ala linker enhances the overall efficacy of the treatment by precise targeting and controlled releasing of the drug payload.
